GE HealthCare Technologies (NASDAQ:GEHC) Posts Earnings Results, Misses Estimates By $0.08 EPS

GE HealthCare Technologies (NASDAQ:GEHC) announced its quarterly earnings data on Wednesday. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08), FiscalAI reports. The business had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.03 billion. GE HealthCare Technologies had a net margin of 10.11% and a return on equity of 21.35%. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.01 EPS. GE HealthCare Technologies updated its FY 2026 guidance to 4.800-5.000 EPS.

Here are the key takeaways from GE HealthCare Technologies’ conference call:

• GE HealthCare reported a strong start to 2026 with $5.1B revenue, 2.9% organic growth, broad geographic strength (double-digit EMEA/ROW, mid-single U.S.) and a record backlog of $21.8 billion.
• Profitability disappointed in Q1 due to a PDX supplier recall (now resolved) and rising material costs, prompting management to lower full-year guidance to an adjusted EPS range of $4.80–$5.00 and reduced free cash flow to about $1.6B.
• Management quantified inflationary headwinds as roughly $250M (≈$0.43/share) — ~ $100M memory chips, ~ $100M oil/freight, and ~$50M other commodities — and expects to offset more than half via price and cost actions, with most mitigation and benefits back‑loaded into H2 and 2027.
• Strategic product and organizational milestones — U.S. and Japan clearances for the Photonova Spectra photon‑counting CT, multiple next‑gen MR FDA clearances, and the creation of a combined Advanced Imaging Solutions segment — position the company to accelerate adoption of high‑margin NPIs that should begin contributing revenue in 1H 2027.
• Progress in Pharmaceutical Diagnostics includes Flyrcado ramping (~80% dose increase since late January, 390 doses the week of April 17) on a path to management’s $500M+ 2028 target, accelerating Vizamyl demand, and a manganese‑based, gadolinium‑free MRI contrast now in combined Phase II/III with FDA Fast Track status.

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC traded down $9.00 on Wednesday, reaching $59.50. 19,237,863 shares of the company were exchanged, compared to its average volume of 3,751,112. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 0.91. GE HealthCare Technologies has a 1-year low of $58.75 and a 1-year high of $89.77. The firm has a market cap of $27.15 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 1.55 and a beta of 1.17. The company has a 50-day moving average of $74.19 and a 200-day moving average of $77.76.

GE HealthCare Technologies Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Friday, April 3rd will be paid a dividend of $0.035 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio is 3.07%.

Institutional Investors Weigh In On GE HealthCare Technologies

A number of large investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. lifted its holdings in GE HealthCare Technologies by 3,084.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 2,388 shares of the company’s stock valued at $179,000 after purchasing an additional 2,313 shares in the last quarter. UMB Bank n.a. lifted its holdings in GE HealthCare Technologies by 36.0% in the 4th quarter. UMB Bank n.a. now owns 1,969 shares of the company’s stock valued at $161,000 after purchasing an additional 521 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in GE HealthCare Technologies in the 4th quarter valued at about $157,000. Ancora Advisors LLC lifted its holdings in GE HealthCare Technologies by 134.6% in the 3rd quarter. Ancora Advisors LLC now owns 2,046 shares of the company’s stock valued at $154,000 after purchasing an additional 1,174 shares in the last quarter. Finally, Summit Securities Group LLC lifted its holdings in GE HealthCare Technologies by 814.0% in the 4th quarter. Summit Securities Group LLC now owns 1,371 shares of the company’s stock valued at $112,000 after purchasing an additional 1,221 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

More GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Revenue beat and underlying growth: Q1 revenue of $5.13B topped estimates and was up ~7.4% YoY, driven by strong performance in Imaging, Advanced Visualization Solutions (AVS), Pharmaceutical Diagnostics (PDx) and services — supporting topline momentum. GE HealthCare reports first quarter 2026 financial results
• Positive Sentiment: Strategic reorganization aimed at scale and focus: Management is combining Imaging and AVS into a $14.6B Advanced Imaging Solutions (AIS) segment and named leadership (Phil Rackliffe as President & CEO of AIS) to drive execution and potential cost synergies. GE HealthCare announces executive team and operational updates
• Neutral Sentiment: Full investor materials available: The company posted its earnings press release, slide deck and conference call recording — useful for parsing margin drivers and management commentary. Earnings materials and transcript
• Negative Sentiment: EPS miss: GAAP EPS was $0.99 vs. consensus ~$1.07, missing estimates and undercutting near‑term investor expectations. GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines
• Negative Sentiment: Guidance cut and margin pressure: FY‑2026 EPS guidance was lowered to $4.80–5.00 vs. street ~5.05; management cited inflation, higher chip/oil/freight costs and tariffs that compressed margins. GE HealthCare cuts annual profit forecast as inflation weighs on costs
• Negative Sentiment: Market reaction and volume spike: Shares fell sharply on the combined effect of the EPS miss, guidance cut and cost concerns, with heavy trading suggesting short‑term investor repositioning. GE HealthCare shares tumble after profit miss and guidance cut

Analyst Ratings Changes

GEHC has been the subject of several analyst reports. Morgan Stanley boosted their price target on shares of GE HealthCare Technologies from $80.00 to $85.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. UBS Group cut shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $73.00 to $77.00 in a report on Thursday, January 15th. Bank of America boosted their price target on shares of GE HealthCare Technologies from $82.00 to $92.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Piper Sandler lowered their price target on shares of GE HealthCare Technologies from $96.00 to $88.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, Stifel Nicolaus boosted their price target on shares of GE HealthCare Technologies from $95.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GE HealthCare Technologies has a consensus rating of “Hold” and a consensus target price of $89.38.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.